Guest: Ilene Galinsky BSN,MSN,ANP-C <br>


  
    <p>Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.</p>

Guest: Ilene Galinsky BSN,MSN,ANP-C Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.

Monitoring for Neutropenia in Acute Myeloid Leukemia

Welcome to the Women’s Health Update series, the latest edition of ReachMD’s Advances in Women’s Health. This series offers insight to improve gynecological care for women. Experts share evidence-based opinions on a variety of topics affecting your patients including: cervical cancer screening, abnormal uterine bleeding, management of preterm birth, and sexually transmitted infections.

Share Monitoring for Neutropenia in Acute Myeloid Leukemia

Sign up to save your podcasts

Monitoring for Neutropenia in Acute Myeloid Leukemia

Monitoring for Neutropenia in Acute Myeloid Leukemia